May Daher

Associate Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

Adoptive cell therapies (ACT) leverage tumor-immune interactions to cure cancer. Despite promising phase I/II clinical trials of chimeric-antigen-receptor natural killer (CAR-NK) cell therapies, molecular mechanisms and cellular properties required to achieve clinical benefits in broad cancer spectra remain underexplored. While in vitro and in vivo experiments are required in this endeavor, they are typically expensive, laborious, and limited to targeted investigations. Here, we present ABMACT (Agent-Based Model for Adoptive Cell Therapy), an in silico approach employing agent-based models (ABM) to simulate the continuous course and dynamics of an evolving tumor-immune ecosystem, consisting of heterogeneous “virtual cells” created based on knowledge and omics data observed in experiments and patients. Applying ABMACT in multiple therapeutic context indicates that to achieve optimal ACT efficacy, it is key to enhance immune cellular proliferation, cytotoxicity, and serial killing capacity. With ABMACT, in silico trials can be performed systematically to inform ACT product development and predict optimal treatment strategies.

Year:

2025

Multiple factors in the design of a chimeric antigen receptor (CAR) influence CAR T-cell activity, with costimulatory signals being a key component. Yet, the impact of costimulatory domains on the downstream signaling and subsequent functionality of CAR-engineered natural killer (NK) cells remains largely unexplored. Here, we evaluated the impact of various costimulatory domains on CAR-NK cell activity, using a CD70-targeting CAR. We found that CD28, a costimulatory molecule not inherently present in mature NK cells, significantly enhanced the antitumor efficacy and long-term cytotoxicity of CAR-NK cells both in vitro and in multiple xenograft models of hematologic and solid tumors. Mechanistically, we showed that CD28 linked to CD3ζ creates a platform that recruits critical kinases, such as lymphocyte-specific protein tyrosine kinase (LCK) and zeta-chain-associated protein kinase 70 (ZAP70), initiating a signaling cascade that enhances CAR-NK cell function. Our study provides insights into how CD28 costimulation enhances CAR-NK cell function and supports its incorporation in NK-based CARs for cancer immunotherapy. Significance: We demonstrated that incorporation of the T-cell–centric costimulatory molecule CD28, which is normally absent in mature natural killer (NK) cells, into the chimeric antigen receptor (CAR) construct recruits key kinases including lymphocyte-specific protein tyrosine kinase and zeta-chain-associated protein kinase 70 and results in enhanced CAR-NK cell persistence and sustained antitumor cytotoxicity.

Year:

2024

Collaborators (16)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Navin Varadarajan

Professor

University of Houston

UNITED STATES
View details

Elizabeth Shpall

Department Chair ad interim

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Biederstädt

Physician Scientist and Junior Group Leader

Technical University of Munich

GERMANY
View details

Francisco Vega

Professor/Chief Lymphoma Section

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Katayoun Rezvani

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Stefano Casarin

Assistant Professor

Houston Methodist

UNITED STATES
View details

Ye Li

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Hind Rafei

Assistant Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Joseph D. Khoury

University of Nebraska Medical Center

UNITED STATES
View details

Rafet Basar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Paul Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pinaki Banerjee

Assistant Professor, Director: Adoptive Cell Therapy Platform Research

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Pei Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ken Chen

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details